REFERENCES
1. Gao YX, Yang TW, Yin JM, et al. Progress and prospects of biomarkers in primary liver cancer (review). Int J Oncol. 2020;57:54-66.
3. Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53.
4. Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Front Oncol. 2020;10:601710.
5. Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: mechanisms of progression and immunotherapy. World J Gastroenterol. 2019;25:3151-67.
7. Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660-5.
8. Lu F, Lan Z, Xin Z, et al. Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases. J Cell Physiol. 2020;235:3207-21.
9. Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro-"host"? Cell Death Dis. 2019;10:650.
10. Wu Y, Zhang J, Yu S, et al. Cell pyroptosis in health and inflammatory diseases. Cell Death Discov. 2022;8:191.
11. Chu Q, Jiang Y, Zhang W, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma. Oncotarget. 2016;7:84658-65.
12. Wei Q, Mu K, Li T, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest. 2014;94:52-62.
13. Meng J, Huang X, Qiu Y, et al. Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. Aging. 2021;13:24379-401.
14. Xiang R, Ge Y, Song W, Ren J, Kong C, Fu T. Pyroptosis patterns characterized by distinct tumor microenvironment infiltration landscapes in gastric cancer. Genes. 2021;12:1535.
15. Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019;19:197-214.
16. Wang L, Qin X, Liang J, Ge P. Induction of pyroptosis: a promising strategy for cancer treatment. Front Oncol. 2021;11:635774.
17. Rao Z, Zhu Y, Yang P, et al. Pyroptosis in inflammatory diseases and cancer. Theranostics. 2022;12:4310-29.
18. Zhang S, Li X, Zhang X, Zhang S, Tang C, Kuang W. The pyroptosis-related gene signature predicts the prognosis of hepatocellular carcinoma. Front Mol Biosci. 2021;8:781427.
19. Fu XW, Song CQ. Identification and validation of pyroptosis-related gene signature to predict prognosis and reveal immune infiltration in hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:748039.
20. Liu S, Shao R, Bu X, Xu Y, Shi M. Identification of the pyroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:742994.
21. Chen X, Lin L, Chen G, et al. High levels of DEAH-box helicases relate to poor prognosis and reduction of DHX9 improves radiosensitivity of hepatocellular carcinoma. Front Oncol. 2022;12:900671.
22. Zhang J, Zong Y, Xu GZ, Xing K. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J. 2016;37:1184-90.
23. Kang YK, Yau T, Park JW, et al. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015;26:2457-63.
24. Sueangoen N, Tantiwetrueangdet A, Panvichian R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci. 2020;10:41.
25. Tan Y, Chen Q, Li X, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40:153.
26. Qu W, Wang Y, Wu Y, et al. Triggering receptors expressed on myeloid cells 2 promotes corneal resistance against pseudomonas aeruginosa by inhibiting caspase-1-dependent pyroptosis. Front Immunol. 2018;9:1121.
27. Wang Y, Cao C, Zhu Y, et al. TREM2/β-catenin attenuates NLRP3 inflammasome-mediated macrophage pyroptosis to promote bacterial clearance of pyogenic bacteria. Cell Death Dis. 2022;13:771.
28. Esparza-Baquer A, Labiano I, Sharif O, et al. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut. 2021;70:1345-61.
29. Schanoski AS, Le TT, Kaiserman D, et al. Granzyme A in chikungunya and other arboviral infections. Front Immunol. 2020;10:3083.
30. Santiago L, Castro M, Sanz-Pamplona R, et al. Extracellular granzyme a promotes colorectal cancer development by enhancing gut inflammation. Cell Rep. 2020;32:107847.
31. Gao Y, Xu Q, Li X, et al. Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma. Cell Death Dis. 2022;13:213.
32. Huang Y, Chen S, Qin W, et al. A novel RNA binding protein-related prognostic signature for hepatocellular carcinoma. Front Oncol. 2020;10:580513.
33. Zhao H, Chen C, Chen X, et al. Analysis of CNOT family gene expression, clinicopathological features, and prognosis value in hepatocellular carcinoma. DNA Cell Biol. 2020;39:5818.
34. Ma X, Qiu Y, Sun Y, et al. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway. Cell Death Dis. 2020;11:174.
35. Tian Z, Hou X, Liu W, Han Z, Wei L. Macrophages and hepatocellular carcinoma. Cell Biosci. 2019;9:79.
36. Zhou L, Wang M, Guo H, et al. Integrated analysis highlights the immunosuppressive role of TREM2+ macrophages in hepatocellular carcinoma. Front Immunol. 2022;13:848367.
37. Shi CX, Wang Y, Chen Q, Jiao FZ, Pei MH, Gong ZJ. Extracellular histone H3 induces pyroptosis during sepsis and may act through NOD2 and VSIG4/NLRP3 pathways. Front Cell Infect Microbiol. 2020;10:196.
38. Wang Q, Zheng K, Tan D, Liang G. TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma. Biochem Biophys Res Commun. 2022;636:140-6.
39. Raza A, Bardhan S, Xu L, et al. A machine learning approach for predicting defluorination of per- and polyfluoroalkyl substances (PFAS) for their efficient treatment and removal. Environ Sci Technol Lett. 2019;6:624-9.
